A Phase 3, randomized, double-blind study with Tivantinib (ARQ 197) in subjects with met diagnostic-high inoperable hepatocellular carcinoma (HCC) treated with one prior systemic therapy
|Effective start/end date||5/1/13 → 8/30/18|
- DAIICHI SANKYO PHARM DEV
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.